Zentalis Pharmaceuticals, Inc.

NASDAQ:ZNTL

Biotechnology

Healthcare
$1.36 +0.83%

+$0.03 today

Market cap
$133.64M
Beta
1.98
P/E (TTM)
-2.1
EPS (TTM)
-$1.77
52W Low $1.13High $6.95

Volume 1.21M

Average 2.00M

ZNTL Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Zentalis Pharmaceuticals, Inc.NASDAQ: ZNTL

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 23.8% from a year ago

Cash & equivalents stood at $31.93M at the end of Q1 FY2026, down 23.8% from a year earlier and down 11.3% from the prior quarter. Over 3 fiscal years it compounded at -5.8% a year.

Context

  • Cash & equivalents amounted to 12.6% of total assets at the end of Q1 FY2026, up 1.7 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -23.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$31.93M-11.3% QoQ
Last fiscal yearDec 2025
$36M+6.2% YoY
Year agoMar 2025
$41.93M-23.8% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.8%——
1 year+6.2%——
3-year CAGR-5.8%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
36M USD
Year-over-year change
+6.2%
4-year CAGR
-12.0%

Cash & Equivalents vs competitors

How ZNTL compares with its peers on the latest reported figures

  • ZNTL's Mar 2026 cash & equivalents of $31.93M is the 8th highest of the 11 companies compared; the peer median is $50.65M.
  • Its year-over-year change of -23.8% is the 5th highest of 11, against a peer median of -30.9%.
  • Cash & equivalents amounts to 12.6% of total assets for ZNTL, versus a peer median of 28.9%.
ZNTL Competitors Peer median
Cash & Equivalents for ZNTL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
DTILPrecision BioSciences, Inc.Mar 2026$99.37M +28.7%-16.4%69.1%
STTKShattuck Labs, Inc.Mar 2026$90.42M +48.5%+4.6%88.5%
IMMXImmix Biopharma, Inc.Mar 2026$79.25M +397.8%+91.2%82.7%
STROSutro Biopharma, Inc.Mar 2026$73.68M -30.6%+7.1%30.4%
MGNXMacroGenics, Inc.Mar 2026$66.52M -54.3%-19.3%30.5%
WHWKWhitehawk Therapeutics IncMar 2026$34.79M -84.7%-1.3%27.3%
ALXOALX Oncology Holdings Inc.Mar 2026$32.28M +56.6%-30.5%18.1%
ZNTLZentalis Pharmaceuticals, Inc.Mar 2026$31.93M -23.8%-5.8%12.6%
PLRXPliant Therapeutics, Inc.Mar 2026$22.19M -75.9%+10.5%11.0%
ARTVArtiva Biotherapeutics, Inc.Mar 2026$20.96M -31.1%-36.1%19.8%
TILInstil Bio, Inc.Mar 2026$5.02M -67.3%-46.7%2.5%
Peer median (excluding ZNTL) $50.65M-30.9%-8.8%28.9%

Competitors are the stored peer set for ZNTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents59.96M43.07M28.04M33.9M36M
Short-term Investments280.17M394.3M454.88M337.18M209.9M
Net Receivables2.64M005M1.93M
Inventory00000
Other Current Assets014.56M13.8M05.37M
Total Current Assets350.77M451.93M496.72M386.07M253.19M
Property, Plant & Equipment (Net)52.84M50.08M41.74M37.23M29.04M
Goodwill3.74M3.74M3.74M00
Intangible Assets00000
Long-term Investments40.12M23.84M2.68M2.63M0
Tax Assets17.52M14.15M10.34M00
Other Non-current Assets7.04M9.72M6.82M4.42M6.74M
Total Non-current Assets121.26M101.52M65.31M44.27M35.78M
Total Assets472.03M553.46M562.03M430.34M288.97M
Account Payables11.59M11.25M14.93M7.44M7.21M
Short-term Debt1.45M02.62M3.07M3.87M
Tax Payables971K0281K00
Deferred Revenue00281K00
Other Current Liabilities20.68M384K(2.9M)29.42M15.51M
Total Current Liabilities43.94M56.65M69.37M52.73M36.56M
Long-term Debt00000
Deferred Tax Liabilities19.14M15M10.34M00
Deferred Revenue (Non-current)00000
Other Non-current Liabilities02.62M1.78M849K500K
Total Non-current Liabilities63.6M62.79M55.27M40.43M36.2M
Total Liabilities107.54M119.43M124.64M93.15M72.76M
Common Stock45K59K70K71K69K
Retained Earnings(359.56M)(596.37M)(888.56M)(1.05B)(1.19B)
Accumulated OCI(125K)(1.35M)2.19M558K196K
Other Stockholders Equity00010
Minority Interest528K221K107K00
Total Equity364.48M434.02M437.39M337.19M216.2M
Total Debt45.91M47.33M45.77M42.65M39.58M
Net Debt(14.05M)4.26M17.74M8.75M3.58M

Zentalis Pharmaceuticals, Inc.

NASDAQ:ZNTL

Intrinsic Alpha fair value

Locked

Current Price

$1.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.